Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TRIM39-RPP21 is a readthrough fusion protein in humans containing the N-terminal tripartite motif (RING, B-box, coiled-coil) of TRIM39 and the C-terminal portion of RPP21, a ribonuclease P subunit. It is transcribed in tissues such as human fetal lung and smooth muscle cells, localizes to intranuclear speckles, and is phosphorylated by cGMP-dependent protein kinase I (PKGI). While it retains characteristics of E3 ubiquitin ligases and RNA-protein complexes, its exact biological role is still poorly understood and it is not established as a recognized drug target or disease biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rpp21 domain-containing TRIM protein (TRIM39-RPP21).